McKesson (MCK) is back on watch after fourth quarter and full year results showed earnings per share above analyst expectations, a revenue shortfall versus estimates, higher buyback authorization, and upbeat FY2027 guidance.

At a share price of $754.76, McKesson’s recent 30 day share price return of 11.89% and 90 day share price return of 20.44% point to fading short term momentum, while the 1 year total shareholder return of 9.78% and very large 5 year total shareholder return suggest longer term holders have still seen strong gains overall.

If the latest results have you thinking about where the next opportunity might come from, this could be a good moment to scan for other healthcare AI stocks using the 35 healthcare AI stocks.

So with analysts’ average price target well above McKesson’s current US$754.76 share price and valuation models pointing to a large intrinsic discount, are you looking at an undervalued compounder, or a stock already pricing in future growth?

Most Popular Narrative: 23.8% Undervalued

With McKesson’s fair value narrative sitting at $990.87 against the recent $754.76 close, the gap comes down to how durable its earnings engine really is.

Increasing complexity of the pharmaceutical supply chain (for example, biosimilars, cold chain logistics, personalized medicine) disproportionately benefits large, sophisticated distributors like McKesson, enabling competitive market share gains and enhanced supply chain resiliency, contributing to both top-line and margin expansion.

Want to see what sits behind that confidence in higher margins and bigger revenue? The narrative leans on steady growth, richer mix, and a premium earnings multiple built on those foundations.

Result: Fair Value of $990.87 (UNDERVALUED)

However, you also need to weigh the pressure on drug pricing and the risk that vertically integrated manufacturers and payers will increasingly squeeze traditional distributors like McKesson over time.

Next Steps

Given the mix of confidence and concern in this narrative, it makes sense to look at the underlying data yourself and decide quickly where you stand using the 4 key rewards and 1 important warning sign.

Looking for more investment ideas?

If this McKesson story has sharpened your focus, do not stop here. Broaden your watchlist with other potential opportunities before the next move passes you by.

• Target stability in your core holdings by scanning 72 resilient stocks with low risk scores, which aims to keep risk scores on the lower side while still offering equity upside.
• Hunt for quality at a sensible entry point using 51 high quality undervalued stocks, which filters for companies with solid cash flows and balance sheets.
• Boost your income focus by reviewing 12 dividend fortresses, which concentrates on stocks offering 5%+ yields with an eye on durability.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.